Industry

Four presentations highlight 12-month clinical outcomes, as well as MRI-assessed joint protection and patient perspectives supporting the SetPoint System as first-of-its-kind treatment for rheumatoid arthritis (RA) VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the … [Read more…]

FRANKLIN, Tenn.–(BUSINESS WIRE)–Community Health Systems, Inc. (NYSE: CYH) announced today that certain subsidiaries of the Company have entered into a definitive agreement to sell 186-bed Regional Hospital of Scranton and 122-bed Moses Taylor Hospital in Scranton, Pennsylvania, 369-bed Wilkes-Barre General Hospital in Wilkes-Barre, Pennsylvania, and certain related businesses to affiliates of Tenor Health Foundation. Since … [Read more…]

BOSTON–(BUSINESS WIRE)–#PR—Ford Hutman Media (“FHM”) and Pinkergreen today announced Greenford, a new firm to support emerging biotech and life-science companies move from stealth to scale with integrated communications, brand strategy, and website development. The firm was founded by two female industry leaders, Rachel Ford Hutman, Co-Founder of Greenford and Principal at FHM, and Kelley Shaw-Wade, … [Read more…]

— XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC — — 25% overall response rate (ORR) observed within the target dose range — — First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort — — Management hosting webcast and conference call today at 1:30 p.m. ET … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Dermal Fillers Market by Brand (Juvederm, Sculptra, Radiesse), Product (Hyaluronic, Collagen, PLLA), Procedure (Skin Rejuvenation, Scar Removal, Face & Body Contouring), End User (Dermatology Clinic, Beauty Centers, Medical Spa) – Global Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The dermal fillers market is expected to experience significant growth, increasing from … [Read more…]

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study … [Read more…]

BALTIMORE–(BUSINESS WIRE)–Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its proprietary Transseptal Puncture Device. This submission marks a major milestone in the Company’s mission to redefine safe, efficient … [Read more…]

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a daratumumab-based triplet2 Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care, and with a new streamlined REMS … [Read more…]

DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for SYD-101, a proprietary 0.01% atropine formulation developed with enhanced ocular delivery characteristics and room-temperature stability to … [Read more…]

First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic ductal adenocarcinoma No nausea, vomiting, or diarrhea greater than Grade 1 was observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with … [Read more…]